8-K: Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements

Alumis Inc. reported its financial results for the quarter ended March 31, 2025, highlighting recent achievements and upcoming milestones, including the pending merger with ACELYRIN and progress in clinical trials.

Summary

• Alumis Inc. reported its financial results for the first quarter of 2025.
• The company is progressing with its clinical trials for ESK-001, with Phase 3 data for plaque psoriasis expected in early Q1 2026 and Phase 2b data for systemic lupus erythematosus expected in 2026.
• Alumis executed a collaboration with Kaken Pharmaceutical for ESK-001 in dermatology in Japan, receiving an upfront license fee of $20.0 million and potential for additional payments.
• The merger with ACELYRIN is expected to close in the second quarter of 2025.
• Alumis stockholders approved the merger with ACELYRIN on May 13, 2025.
• ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned.
• Alumis stockholders will own approximately 52% of the combined company, and ACELYRIN stockholders will own approximately 48% on a fully diluted basis.
• The combined company's pro forma cash position is expected to be approximately $737 million as of December 31, 2024, providing runway into 2027.
• As of March 31, 2025, Alumis had cash, cash equivalents, and marketable securities of $208.7 million.
• Revenue for the quarter ended March 31, 2025, included license revenue of $17.4 million from the Kaken collaboration.
• Research and development expenses were $96.6 million for the quarter ended March 31, 2025, compared to $42.0 million for the quarter ended March 31, 2024.
• General and administrative expenses were $22.3 million for the quarter ended March 31, 2025, compared to $5.6 million for the quarter ended March 31, 2024.
• Net loss was $99.0 million for the quarter ended March 31, 2025, compared to $49.8 million for the quarter ended March 31, 2024.
• Alumis expects its R&D expenses to significantly decrease for the subsequent quarters of 2025.
• Alumis anticipates that its existing cash will support operations into 2026, through the Phase 3 ONWARD program clinical data readout expected in early Q1 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a larger net loss, it also highlighted progress in clinical trials, a significant collaboration, and the pending merger, which are all positive developments. The increased R&D spending, while contributing to the loss, also indicates investment in future growth.

Positives

• The Kaken collaboration provides an upfront license fee of $20.0 million and potential for additional payments, leveraging Kaken's regional expertise.
• The merger with ACELYRIN is expected to close soon, enhancing financial flexibility with a pro forma cash position of approximately $737 million as of December 31, 2024.
• Alumis stockholders approved the merger with ACELYRIN on May 13, 2025.
• The company anticipates existing cash will support operations into 2026, through the Phase 3 ONWARD program clinical data readout expected in early Q1 2026.

Negatives

• The net loss for the quarter ended March 31, 2025, was $99.0 million, compared to $49.8 million for the same period in 2024.
• Research and development expenses increased significantly to $96.6 million for the quarter ended March 31, 2025, compared to $42.0 million for the quarter ended March 31, 2024.
• General and administrative expenses increased to $22.3 million for the quarter ended March 31, 2025, compared to $5.6 million for the quarter ended March 31, 2024.

Risks

• The merger with ACELYRIN may not be completed in a timely manner or at all.
• The anticipated benefits and synergies of the proposed transaction may not be fully realized or may take longer to realize than expected.
• Clinical trial results may not be favorable, impacting the development of ESK-001 and A-005.
• Regulatory approvals for Alumis' product candidates may not be obtained or may be delayed.
• The company may face challenges in commercializing its product candidates, if approved.

Future Outlook

Alumis anticipates that its existing cash will support operations into 2026, through the Phase 3 ONWARD program clinical data readout expected in early Q1 2026. Assuming successful close of the merger with ACELYRIN, the combined company's pro forma cash position of approximately $737 million as of December 31, 2024, is expected to provide runway to advance its pipeline through multiple planned key clinical data readouts and to fund operating expenses and capital expenditure requirements into 2027.

Management Comments

• 'Were seeing strong momentum across our development programs, with our team continuing to execute effectively following a productive first quarter of 2025,' said Martin Babler, President and Chief Executive Officer of Alumis.
• Babler continued, 'We are also focused on the anticipated close of the merger with ACELYRIN in the second quarter of this year.'

Industry Context

The announcement reflects the ongoing trend of consolidation in the biopharmaceutical industry, with companies seeking to enhance their pipelines and financial resources through mergers and collaborations. The focus on immune-mediated diseases aligns with the growing market for targeted therapies in this area.

Comparison to Industry Standards

• The increase in R&D spending is typical for clinical-stage biopharmaceutical companies advancing multiple programs.
• The collaboration with Kaken is similar to other licensing agreements in the industry, where companies leverage regional expertise for commercialization.
• The pro forma cash position of $737 million for the combined company is competitive with other companies in the sector, providing a runway into 2027.

Stakeholder Impact

• Shareholders will be impacted by the merger with ACELYRIN, with ownership percentages changing.
• Employees may experience changes due to the integration of Alumis and ACELYRIN.
• Patients may benefit from the advancement of new therapies for immune-mediated diseases.
• The Kaken collaboration may lead to broader access to ESK-001 in Japan.

Next Steps

• Closing of the merger with ACELYRIN in Q2 2025.
• Initiation of Phase 2 clinical trial for A-005 in multiple sclerosis (MS) in 2025.
• Finalizing clinical development plan for Lonigutamab following the closing of the merger with ACELYRIN in mid-2025.
• Filing Investigational New Drug Application for third clinical candidate in 2025.
• Reporting ESK-001 Psoriasis Phase 3 topline data in Q1 2026.
• Reporting ESK-001 SLE Phase 2b topline data in 2026.
• Reporting A-005 MS Phase 2 topline data in 2026.

Key Dates

Keywords

Alumis, ACELYRIN, Merger, ESK-001, Clinical Trials, Financial Results, Kaken Pharmaceutical, TYK2 Inhibitor, Psoriasis, SLE